Oxford Biomedica Future Growth

Future criteria checks 5/6

Oxford Biomedica is forecast to grow earnings and revenue by 93.2% and 21% per annum respectively. EPS is expected to grow by 100.7% per annum. Return on equity is forecast to be -21% in 3 years.

Key information

93.2%

Earnings growth rate

100.7%

EPS growth rate

Biotechs earnings growth37.2%
Revenue growth rate21.0%
Future return on equity-21.0%
Analyst coverage

Good

Last updated06 Nov 2024

Recent future growth updates

Recent updates

Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Oct 19
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Aug 23
Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 15
Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Oct 06
Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

May 02
Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn

Jun 29
We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn

Earnings and Revenue Growth Forecasts

LSE:OXB - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026212821338
12/31/2025167-16-168
12/31/2024130-38-26-218
6/30/202497-142-72-62N/A
3/31/202493-150-55-45N/A
12/31/202390-157-38-29N/A
9/30/2023104-110-24-11N/A
6/30/2023119-62-96N/A
3/31/2023130-50-19-3N/A
12/31/2022140-39-29-13N/A
9/30/2022133-32-31-17N/A
6/30/2022126-25-33-21N/A
3/31/2022134-3-92N/A
12/31/2021143191625N/A
9/30/2021139191526N/A
6/30/2021135191526N/A
3/31/20211116215N/A
12/31/202088-6-103N/A
9/30/202077-9-16-1N/A
6/30/202066-13-22-6N/A
3/31/202065-14-26-5N/A
12/31/201964-16-29-4N/A
9/30/201964-12-26-4N/A
6/30/201964-8-23-4N/A
3/31/2019650-104N/A
12/31/2018678313N/A
9/30/2018624918N/A
6/30/20185701623N/A
3/31/201847-5N/A13N/A
12/31/201738-9N/A3N/A
9/30/201734-10N/A-1N/A
6/30/201731-11N/A-6N/A
3/31/201729-14N/A-4N/A
12/31/201628-17N/A-2N/A
9/30/201626-16N/A-1N/A
6/30/201624-16N/A-1N/A
3/31/201620-15N/A-7N/A
12/31/201516-13N/A-13N/A
9/30/201515-12N/A-12N/A
6/30/201513-10N/A-10N/A
3/31/201513-9N/A-8N/A
12/31/201414-9N/A-6N/A
9/30/201411-9N/A-8N/A
6/30/20148-10N/A-9N/A
3/31/20147-11N/A-10N/A
12/31/20135-11N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: OXB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OXB is expected to become profitable in the next 3 years.

Revenue vs Market: OXB's revenue (21% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: OXB's revenue (21% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OXB is forecast to be unprofitable in 3 years.


Discover growth companies